Project Grant R01EY035092

Award Date 6/1/24
Completion Date 5/31/28
Dollars Obligated $1.6M
Federal Grant Program
93.867
Assistance Type
Project Grant
Place of Performance
Aurora, CO 80045, USA
Similar Awards
This Project Grant award from the National Eye Institute (CFDA 93.867 Vision Research) for $3,120,397 will support the development and characterization of a 3D tissue chip model of the retinal pigment epithelium (RPE)-choroid complex to study the role of genetic risk factors and environmental stressors in the early pathogenesis of age-related macular degeneration (AMD). The research team, led by investigators at the Medical University of South Carolina, will utilize induced pluripotent stem...
This Project Grant award from the National Eye Institute (CFDA 93.867 - Vision Research) provides $618,600 to The University of Iowa to develop advanced cell culture and imaging technologies to improve the production and assessment of autologous induced pluripotent stem cell (iPSC)-derived retinal tissues for the treatment of inherited retinal degenerative blindness. The key objectives are to: 1) Use machine learning to analyze iPSC generation and retinal differentiation imaging data to identify...
This Project Grant award from the National Eye Institute (NEI), under the federal Vision Research program (CFDA 93.867), aims to develop universally immune-compatible induced pluripotent stem cells (iPSCs) for regenerative therapies to treat various eye conditions. The $492,500 award, granted on January 1, 2025, supports research at The Schepens Eye Research Institute, Inc. to generate iPSCs that express peptide-free or low-affinity peptide-loaded HLA-I molecules, protecting them from...
This Project Grant award from the National Eye Institute (NEI) of the National Institutes of Health (CFDA 93.867 - Vision Research) provides $658,889 to the University of Rochester to investigate the role of the pro-inflammatory enzyme PLA2G2A/sPLA2-IIA in age-related macular degeneration (AMD). The research aims to utilize human donor eyes, patient-derived induced pluripotent stem cells, and transgenic mouse models to critically evaluate the mutation-independent pathogenic role of PLA2G2A in...
This Project Grant award from the National Eye Institute (CFDA 93.867 Vision Research) provides $253,500.00 to the Icahn School of Medicine at Mount Sinai to reconstruct a human blood-retina barrier and perfused vascular system. The goal is to investigate the role of apolipoprotein E (APOE) variants in age-related macular degeneration (AMD), a leading cause of vision loss. The research aims to optimize an in vitro outer blood-retina barrier model, generate isogenic models with different APOE...
This $428,349 Project Grant awarded by the National Eye Institute (CFDA 93.867 Vision Research) supports research by The Medical College of Wisconsin, Inc. to investigate the mechanisms controlling the development of retinal ganglion cells (RGCs). The key objectives are to: Examine the shared cis-regulatory elements and target genes of the transcription factors ATOH7, POU4F2, and ISL1 that are critical for RGC genesis. This will involve testing their spatial-temporal expression patterns in...
This $380,000 Project Grant award from the National Eye Institute (NEI), under the Vision Research program (CFDA 93.867), supports research to investigate the role of interphotoreceptor matrix proteoglycans in retinal homeostasis and retinitis pigmentosa. The project aims to: 1) Explore how the proteoglycans IMPG1 and IMPG2 facilitate nutrient exchange between the retina and retinal pigment epithelium, and how mutations in these molecules lead to adult-onset retinitis pigmentosa; 2) Determine...
This $1,330,026 Project Grant awarded by the National Eye Institute (CFDA 93.867 - Vision Research) will support the development of two new mouse models of geographic atrophy, the advanced form of dry age-related macular degeneration (AMD). The goal is to use these models to evaluate the potential of a novel antioxidant, deuterated docosahexaenoic acid (D-DHA), to protect the retinal pigment epithelium and prevent or treat AMD progression. The research will be conducted by the University of...
This Project Grant award of $620,149 from the National Eye Institute (NEI), under the Vision Research federal grant program (CFDA 93.867), supports a multi-center research program to develop advanced genome editing technologies for modifying critical genetic risk factors associated with age-related macular degeneration (AMD). The research team, led by the University of Iowa, will conduct base editing and prime editing of AMD risk loci in human cells, including induced pluripotent stem...
The National Eye Institute (NEI) awarded a $240,000 Project Grant (CFDA 93.867 - Vision Research) to Baylor College of Medicine to conduct research focused on "Characterization of the Nascent Retinal Proteome Regulating Hippo Signaling During Damage." The project aims to use cell type-specific metabolic labeling and purification techniques to identify the immediate molecular regulators of the Hippo signaling pathway in muller glial cells of the damaged mouse retina. This information is...

CELL-BASED THERAPIES FOR RETINAL DEGENERATION - PROJECT SUMMARY/ABSTRACT THIS PROJECT ADDRESSES THE NEI AUDACIOUS GOAL INITIATIVE (AGI) OF RESTORING VISION THROUGH REGENERATION OF PHOTORECEPTOR CELLS AND THEIR CONNECTIONS. AMONG DEGENERATIVE DISEASES OF THE OUTER RETINA AMENABLE TO REGENERATIVE THERAPIES, DRY AGE-RELATED MACULAR DEGENERATION (AMD) IS A MAJOR TARGET. AMD IS THE LEADING CAUSE OF IRREVERSIBLE BLINDNESS IN DEVELOPED COUNTRIES, WITH THE DRY FORM ACCOUNTING FOR NEARLY 90% OF PATIENTS AFFECTED BY THIS CONDITION. PATIENTS WITH END-STAGE DRY-AMD PRESENT MACULAR PHOTORECEPTOR AND RETINAL PIGMENT EPITHELIUM (RPE) ATROPHY, AND THERE IS NO AVAILABLE TREATMENT THAT CAN RESTORE THEIR LOST VISION. TO ADDRESS THIS IMPORTANT UNMET NEED WE NEED TO ADDRESS TWO CRITICAL GAPS: DEVISING NOVEL CELL-BASED TRANSPLANTATION STRATEGIES TO JOINTLY REGENERATE PHOTORECEPTOR AND RPE CELLS, AND IDENTIFYING MECHANISMS SUPPORTING STRUCTURAL AND FUNCTIONAL INTEGRATION OF THE TRANSPLANTED CELLS. THE GOAL OF THIS PROJECT IS TO DIRECTLY ADDRESS THESE TWO CRITICAL GAPS BY ESTABLISHING FEASIBILITY AND MECHANISMS OF STRUCTURAL AND FUNCTIONAL INTEGRATION OF A NOVEL STEM CELL-DERIVED 3D RETINAL TRANSPLANT CONTAINING PHOTORECEPTORS AND RPE (3DNR/RPE) IN A MINIPIG MODEL OF END- STAGE MACULAR ATROPHY. OUR PRELIMINARY RESULTS SHOWED SURVIVAL OF OUR 3DNR/RPE TRANSPLANTS WITHIN THE SUBRETINAL SPACE OF OUR MINIPIG MODEL. THIS WAS ACCOMPANIED BY INCREASED LIGHT RESPONSE SIX WEEKS POST- TRANSPLANTATION. THESE RESULTS STRONGLY SUPPORT OUR OVERARCHING HYPOTHESIS: THAT HUMAN INDUCED PLURIPOTENT STEM CELLS (HIPSC)-DERIVED 3DNR/RPE TRANSPLANTS ACHIEVE STRUCTURAL AND FUNCTIONAL INTEGRATION. IN THESE STUDIES, WE WILL USE AN ARRAY OF COMPLEMENTARY MULTIMODAL IN VIVO OCULAR EVALUATION, EX VIVO ASSESSMENTS, AND NON-INVASIVE IN VIVO FUNCTIONAL IMAGINING TO DETERMINE THE EXTENT OF STRUCTURAL AND FUNCTIONAL INTEGRATION OF OUR HIPSC-DERIVED 3DNR/RPE TRANSPLANTS. WE WILL SPECIFICALLY TEST THE FOLLOWING HYPOTHESES: I) CO-TRANSPLANTED PHOTORECEPTORS AND RPE RE-ESTABLISH PHYSIOLOGICAL AND FUNCTIONAL INTERACTIONS; II) TRANSPLANTED PHOTORECEPTORS SYNAPSE WITH BOTH, CO-TRANSPLANTED AND HOST BIPOLAR CELLS, WHICH IN TURN COMMUNICATE WITH HOST AMACRINE AND/OR GANGLION CELLS; III) 3DNR/RPE TRANSPLANTS LEAD TO INCREASED LIGHT RESPONSE FROM ALL PHOTORECEPTOR CELL TYPES; AND IV) 3DNR/RPE TRANSPLANTS LEAD TO LIGHT-TRIGGERED RESPONSE IN BIPOLAR AND GANGLION CELLS. THIS IS A HIGHLY INNOVATIVE STRATEGY GROUNDED IN OUR ABILITY TO GENERATE RETINAL TISSUE TRANSPLANTS DERIVED FROM HIPSC THAT CONTAIN FUNCTIONAL LIGHT-SENSITIVE PHOTORECEPTORS AND RPE CELLS ORGANIZED AS IN THE NATIVE RETINA. USE OF NOVEL HIGH-RESOLUTION TECHNOLOGY FOR NON-INVASIVE FUNCTIONAL ASSESSMENT OF TRANSPLANT INTEGRATION IS AN ADDITIONAL INNOVATIVE ASPECT OF OUR PROPOSED STUDIES. THE POTENTIAL IMPACT OF OUR STUDIES IS HIGHLY SIGNIFICANT AS IT COULD LEAD TO CRITICAL PRECLINICAL EVIDENCE SUPPORTING THE FEASIBILITY OF HIPSC-DERIVED 3DNR/RPE TRANSPLANTS FOR CELL- REPLACEMENT THERAPY. IN TURN, THIS TRANSPLANT STRATEGY COULD BECOME THE FIRST AVAILABLE SOLUTION FOR RESTORING VISION IN PATIENTS AFFECTED BY END-STAGE DRY-AMD.

Posted 5/17/24, 12:00 AM